Shares of Sarepta Therapeutics SRPT decreased in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 17.20% over the past year to ($1.84), which missed the estimate of ($1.77).
Revenue of $145,138,000 higher by 44.97% from the same period last year, which missed the estimate of $146,290,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Sarepta Therapeutics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Mar 01, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/r73teqoz
Recent Stock Performance
52-week high: $181.83
52-week low: $77.01
Price action over last quarter: down 30.77%
Company Overview
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
